

London closed lower as bumper profits at US investment bank Goldman Sachs failed to spark Wall Street, which has retreated from the 10,000 mark hit la...


Bumper profits at US investment bank Goldman Sachs have failed to ignite fresh buying interest on Wall Street, leaving London weaker as resource plays...


Oxford Biomedica doubled at one stage Thursday after it said patients taking part in a Phase I/II trial of its Parkinson's disease drug ProSavin have ...


J Sainsbury is the stand-out riser so far on talk that the Qatar investors in the supermarket are looking to build on their current 26% stake, but it ...


Oxford Biomedica doubled at one stage Thursday after it said patients taking part in a Phase I/II trial of its Parkinson's disease drug ProSavin have ...


Shares in Oxford BioMedica dropped after interim results from a Phase III study of the gene therapy company's cancer vaccine TroVax did not show a 'si...


Identity management specialists GB Group was slightly lower despite saying that interim pre-tax profit was marginally ahead of the same period last ye...


Alizyme has lost chief executive Tim McCarthy as part of the drug developer's reconstruction effort. Non-executive director Alan Goodman will take ch...